Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

Khoon Lee, Chee; Man, Johnathan; Lord, Sally; A. Cooper, Wendy; Links, Matthew; Gebski, Val; S. Herbst, Roy; J. Gralla, Richard; Mok, Tony; Chih‐Hsin Yang, James

doi:10.1001/jamaoncol.2017.4427

Public

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

Published in JAMA Oncology • Dec 21, 2017

Authors:

Chee Khoon Lee

Johnathan Man

Sally Lord

Abstract

IMPORTANCE: Checkpoint inhibitors have replaced docetaxel as the new standard second-line therapy in advanced non-small cell lung carcinoma (NSCLC), but little is known about the potential predictive value of clinical and molecular characteristics. OBJECTIVE: To estimate the relative efficacy of che...

Subject

Medicine

Atezolizumab

Docetaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!